Semaglutide Shows Significant Efficacy in Advanced Liver Disease Mouse Model
Background
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a severe form of fatty liver disease characterized by inflammation, liver cell damage, and fibrosis, often progressing to cirrhosis and liver failure. Currently, there are no FDA-approved pharmacological treatments specifically for MASH, representing a critical unmet medical need. While GLP-1 receptor agonists like semaglutide have shown promise in earlier stages of MASH, the efficacy and translatability of semaglutide in a liver biopsy-confirmed, advanced MASH model with significant fibrosis remained underexplored.
Results
Treatment with semaglutide significantly improved key MASH pathologies and metabolic parameters. Treated mice exhibited a 22% reduction in body weight and a 35% improvement in glucose tolerance compared to controls. Histological analysis revealed a remarkable 58% reduction in liver steatosis and a 45% decrease in lobular inflammation. Furthermore, semaglutide treatment led to a significant 43% reduction in liver fibrosis scores, indicating a direct impact on disease progression. > The most striking finding was a 2.5-fold decrease in the overall NAFLD Activity Score (NAS) in the semaglutide group (p<0.001), demonstrating a comprehensive improvement across multiple MASH features. These improvements were accompanied by favorable changes in circulating MASH-related biomarkers, suggesting high translatability.
Why It Matters
This study provides compelling evidence that semaglutide is highly effective in reversing advanced MASH pathology, including significant liver fibrosis, in a robust and clinically relevant animal model. The observed improvements in both metabolic parameters and direct liver histology, coupled with favorable biomarker signatures, strongly support its potential as a therapeutic agent for MASH. These findings underscore the urgent need for further clinical investigation of semaglutide as a potential first-in-class treatment for patients with advanced MASH. Future steps should include larger Phase II and Phase III human clinical trials specifically designed to evaluate semaglutide's efficacy in biopsy-confirmed MASH patients.